Idiopathic pulmonary fibrosis in detail

Reading Document

Medical Text Search

idiopathic pulmonary fibrosis etiology pathophysiology clinical features diagnosis

Medical Text Search

idiopathic pulmonary fibrosis treatment management antifibrotic prognosis

Medical Image Search

idiopathic pulmonary fibrosis HRCT usual interstitial pneumonia UIP pattern

GradeResponse

Here is a comprehensive overview of idiopathic pulmonary fibrosis (IPF):

Idiopathic Pulmonary Fibrosis (IPF)

Definition

IPF is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, associated with the radiological and histopathological pattern of Usual Interstitial Pneumonia (UIP). It occurs primarily in older adults and carries a poor prognosis. (ATS/ERS Guidelines, p. 2)

Epidemiology

Parameter	Detail
Age of onset	Typically >60 years (rare <50)
Sex	Male predominance (~2:1)
Prevalence	~13–20 per 100,000 (higher in older populations)
Incidence	Increasing globally

Risk factors:

Cigarette smoking (strongest environmental risk; ~75% of patients are current or ex-smokers)
Occupational dust exposures (wood, metal, agricultural dust)
Gastroesophageal reflux disease (GERD)
Viral infections (EBV, CMV, HHV-8)
Genetic predisposition — MUC5B promoter variant (rs35705950) is the most common genetic risk factor; also TERT, TERC, SFTPC, SFTPA2 mutations (telomere/surfactant biology)
Family history (familial IPF = ~5% of cases)

Pathophysiology

The prevailing model is one of aberrant wound healing rather than primary inflammation:

Repetitive alveolar epithelial injury → apoptosis of type II pneumocytes in genetically susceptible individuals
Dysregulated repair → abnormal activation and proliferation of fibroblasts/myofibroblasts
Fibroblastic foci form — hallmark histological feature — with excessive deposition of extracellular matrix (collagen)
Key mediators:
- TGF-β1 (master profibrotic cytokine)
- PDGF, VEGF, FGF
- Epithelial-mesenchymal transition (EMT)
- Oxidative stress, telomere shortening, senescence
Progressive architectural distortion → honeycombing → respiratory failure

The inflammatory cascade is now considered secondary, not causal — explaining why anti-inflammatory therapies fail.

Clinical Features

Symptoms

Progressive exertional dyspnea (insidious onset, months–years)
Dry, persistent cough (often refractory)
Fatigue, weight loss (late)
Rare: pleuritic chest pain

Signs

Bibasal fine inspiratory ("Velcro") crackles — hallmark
Clubbing (~50%)
Cyanosis and signs of pulmonary hypertension (right heart failure) in advanced disease

Diagnosis

Diagnosis requires multidisciplinary discussion (MDD) involving pulmonologist, radiologist, and pathologist. Key steps:

Step 1: Exclude Other Causes of ILD

Connective tissue disease (CTD-ILD): SLE, RA, SSc, PM/DM
Hypersensitivity pneumonitis (HP)
Drug-induced ILD (amiodarone, methotrexate)
Occupational/environmental ILD
Sarcoidosis

Step 2: High-Resolution CT (HRCT) — Pattern Classification

HRCT is the cornerstone of diagnosis. The UIP pattern is classified as:

HRCT Category	Features	Surgical Biopsy Needed?
Typical UIP	Bilateral, subpleural, basal-predominant; honeycombing ± traction bronchiectasis; no features against UIP	No
Probable UIP	Reticular pattern, traction bronchiectasis, no honeycombing; subpleural, basal	May need biopsy
Indeterminate for UIP	Subtle reticulation; may have features atypical for UIP	Often needs biopsy
Alternative diagnosis	Features suggesting another ILD	Biopsy or alternative workup

HRCT — Typical UIP Pattern

HRCT showing definite UIP pattern in IPF — bilateral subpleural honeycombing, traction bronchiectasis, and reticular opacities with basal predominance

Axial HRCT demonstrating the "definite UIP" pattern: bilateral subpleural honeycombing (clustered thick-walled cysts), traction bronchiectasis within fibrotic areas, and a peripheral reticular pattern with basal predominance — classic for IPF.

Step 3: Histopathology (when needed)

Surgical lung biopsy (VATS) or transbronchial lung cryobiopsy (TBLC) — TBLC now conditionally recommended as a less invasive alternative.

UIP histologic features:

Fibroblastic foci (key feature)
Patchy fibrosis with temporal heterogeneity (old + new fibrosis coexisting)
Honeycombing (subpleural, basal)
Minimal inflammation

Step 4: Additional Diagnostics

Test	Purpose
PFTs	Restrictive pattern: ↓TLC, ↓FVC, ↓DLCO, normal or ↑FEV1/FVC
6-Minute Walk Test (6MWT)	Exercise capacity, baseline and monitoring
BAL (bronchoalveolar lavage)	Exclude HP, eosinophilia, infection
Serologies (ANA, RF, anti-CCP, anti-Jo-1, etc.)	Exclude CTD-ILD
Genomic classifier testing	Peripheral blood test (Envisia) to distinguish UIP vs non-UIP — newly addressed in 2022 guidelines
Echocardiography	Screen for pulmonary hypertension
Sleep study	Screen for OSA (common comorbidity)

Differential Diagnosis

Condition	Key Distinguishing Feature
HP (chronic)	Upper/mid-lobe predominance, centrilobular nodules, exposure history
NSIP	Bilateral GGO, subpleural sparing, younger age, CTD association
Cryptogenic organizing pneumonia	Consolidation, peribronchovascular, responds to steroids
Sarcoidosis	Upper lobe, lymphadenopathy, non-caseating granulomas
Asbestosis	Pleural plaques, occupational history
CTD-ILD (RA, SSc)	Serological markers, systemic features

Management

(ATS/ERS Guidelines, p. 18)

Pharmacological Treatment

Antifibrotic Agents (Disease-Modifying)

Drug	Mechanism	Dose	Key Side Effects
Pirfenidone (Esbriet)	Anti-inflammatory, antifibrotic, antioxidant; inhibits TGF-β	2403 mg/day (tid)	Nausea, rash, photosensitivity, ↑LFTs
Nintedanib (Ofev)	Tyrosine kinase inhibitor (PDGFR, FGFR, VEGFR)	150 mg bid	Diarrhea, nausea, ↑LFTs, teratogenic

Both drugs reduce FVC decline by ~50% and reduce acute exacerbation risk. They do not reverse fibrosis but slow progression. Both are conditionally recommended by ATS/ERS guidelines; choice is individualized based on comorbidities and tolerability.

Not recommended: Corticosteroids (alone or combined with azathioprine + N-acetylcysteine), anticoagulation (warfarin), sildenafil for ILD-related dyspnea, and imatinib.

Non-Pharmacological Management

Intervention	Indication/Detail
Long-term oxygen therapy	Resting hypoxemia (SpO₂ <88%) or exertional desaturation
Pulmonary rehabilitation	Improves exercise tolerance, dyspnea, QoL
Lung transplantation	Definitive treatment; single or bilateral; refer early (at diagnosis if high-risk features); 5-year survival ~50%
Antacid therapy (PPIs/H2 blockers)	GERD treatment recommended (GERD highly prevalent; micro-aspiration may drive injury)
Palliative care	Symptom management (cough, dyspnea, anxiety, depression); discuss early

Comorbidity Management

Comorbidity	Approach
Pulmonary hypertension	Evaluate with echo/RHC; consider targeted therapy
OSA	CPAP; very common in IPF
Lung cancer	IPF is an independent risk factor; screen per guidelines
GERD	Treat aggressively
Coronary artery disease	Common in same demographic

Acute Exacerbations of IPF (AE-IPF)

Definition: Acute worsening with new bilateral GGO/consolidation on HRCT (beyond background UIP) with no identifiable cause
Triggers: Infection, aspiration, surgery, bronchoscopy — or idiopathic
Incidence: ~5–10%/year
Management:
- High-dose corticosteroids (empiric, evidence limited)
- Broad-spectrum antibiotics (to cover secondary infection)
- Supportive oxygen; mechanical ventilation generally NOT recommended (poor outcomes)
- ICU admission often futile — goals-of-care discussion essential
Prognosis: In-hospital mortality ~50%; median survival after AE-IPF ~3–4 months

Monitoring

Patients should be evaluated every 3–6 months (more frequently if progressing) with:

Spirometry + DLCO
6MWT
HRCT (annually or if significant change)
Assessment for transplant candidacy

Markers of disease progression / poor prognosis:

FVC decline ≥10% over 6–12 months
DLCO decline ≥15%
Desaturation during 6MWT
Hospitalization for respiratory cause
Development of pulmonary hypertension

Prognosis

Parameter	Data
Median survival from diagnosis	3–5 years
5-year mortality	~80%
Cause of death	Respiratory failure (most common), AE-IPF, lung cancer, cardiovascular

IPF follows a variable course — most patients show slow, steady decline; some have accelerated decline with AEs; a minority are stable for years.

Key Guidelines

ATS/ERS/JRS/ALAT 2022 Clinical Practice Guidelines — the most current evidence-based guideline (ATS/ERS, p. 2, 18)
Available at: American Journal of Respiratory and Critical Care Medicine

Summary Algorithm

Suspected IPF (older adult, bilateral basal crackles, dyspnea)
        ↓
Exclude alternative ILD causes (CTD serology, drug Hx, exposure Hx)
        ↓
HRCT
   ├── Typical UIP → Diagnose IPF (no biopsy needed)
   ├── Probable UIP → Consider biopsy / genomic classifier / MDD
   └── Indeterminate → Biopsy (TBLC or surgical) → MDD
        ↓
Confirm IPF
        ↓
Start antifibrotic (nintedanib or pirfenidone)
+ O₂, pulmonary rehab, GERD treatment
+ Early lung transplant referral if high-risk
+ Monitor every 3–6 months
+ Palliative care integration

This is a shared conversation. Sign in to Orris to start your own chat.